The short answer
Excessive caffeine should be avoided while taking tranylcypromine. Large amounts may cause a dangerous rise in blood pressure. The evidence does not make every cup of coffee equivalent to a concentrated caffeine supplement; discuss your total caffeine intake with your prescriber.
What this answer covers
Oral tranylcypromine tablets with caffeine from drinks, tablets, powders or other supplements. The concern depends on total exposure; no universal safe amount has been established for this combination.
- Supplement or preparation
- Caffeine
- Medication ingredient
- tranylcypromine
Count the whole day
Caffeine in a pre-workout powder or energy product adds to caffeine from coffee, tea and guarana. Bring the ingredient list and your usual drink intake to the clinician managing tranylcypromine; a supplement name alone may not show the caffeine amount.
What the evidence shows
The medication warning is specifically about excessive amounts. In one report, a man drinking 10 to 12 cups of coffee daily developed severe hypertension after tranylcypromine was increased. Stopping caffeinated coffee improved his readings while treatment continued. That observation does not set a safe dose for anyone else.
Spacing does not establish safety
Taking caffeine several hours away from the antidepressant has not been shown to prevent this interaction. Ask about an intake plan rather than changing or stopping the prescription yourself.
Symptoms that need urgent attention
Seek urgent medical care for a sudden severe headache, chest pain, marked palpitations, confusion or a severe blood-pressure rise. Tell the treating team about the MAOI and any caffeine or stimulant products.
Evidence and practical considerations
Side effects & toxicity
Current medication labeling warns against excessive caffeine. A direct case report documents severe hypertension during heavy coffee intake and tranylcypromine, with improvement after caffeinated coffee was withdrawn.
- Exact scope
- Oral tranylcypromine tablets with caffeine from drinks, tablets, powders or other supplements. The concern depends on total exposure; no universal safe amount has been established for this combination. with Oral tranylcypromine tablets; current sulfate-tablet labeling uses the named active ingredient.
- Medication form and route
- oral
What remains uncertain
- The label does not define an individual safe caffeine threshold. The direct evidence is one high-exposure case, not a dose-ranging trial.
Factors that may matter: Exact supplement preparation and complete concomitant-medication list require assessment..
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral tranylcypromine sulfate tablets.
The label contraindicates sympathomimetic supplements, hydroxytryptophan, tryptophan and SAM-e; it names St. John's wort in the serotonin-syndrome warning and lists excessive caffeine among exposures to avoid.
How this applies: Primary authority for exact tranylcypromine tablet precautions. Named supplements and class-based applications are kept distinct.
A labeled contraindication is not a measurement of the frequency of an event with each product; L-tyrosine and Panax ginseng are not individually named.
Source 2: Federal ingredient information
ods.od.nih.gov · Source check Sep 10, 2026
Population: Consumers of caffeine and botanical dietary supplements.
Guarana and tea can contribute caffeine, and a botanical ingredient list may omit the amount of caffeine. Caffeine has stimulant effects.
How this applies: General healthy-adult caffeine limits are not safety limits for patients receiving MAOIs. No exact guarana-MAOI trial is supplied.
General healthy-adult caffeine limits are not safety limits for patients receiving MAOIs. No exact guarana-MAOI trial is supplied.
Source 3: Human case report
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: One 56-year-old man with previously treated hypertension and major depressive disorder.
Severe hypertension improved after caffeinated coffee was withdrawn while tranylcypromine continued; normal pressure persisted with decaffeinated coffee.
How this applies: Direct coexposure evidence for caffeine-containing coffee and tranylcypromine, not a trial of caffeine tablets or another MAOI.
Single uncontrolled case; high tranylcypromine dose, prior hypertension, smoking and other exposures limit generalization. No safe caffeine threshold was established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial targeted research draft. Inspected source material, adjudicated the current checker statements, and recorded preparation limits. Clinical review has not occurred. | |
| Research summary published |
Article revision: 5adecf6613827757
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.